Inactive Instrument

The iQ Group Global Ltd.

Equities

IQG

AU0000080277

The Iq Group Global Ltd. Reports Earnings Results for the Full Year Ended June 30, 2020

September 12, 2020 at 01:52 pm IST

The iQ Group Global Ltd. announced earnings results for the full year ended June 30, 2020. For the full year, the company announced sales was AUD 15.448 million compared to AUD 12.604 million a year ago. Net loss was AUD 19.276 million compared to AUD 12.183 million a year ago. Basic loss per share from continuing operations was AUD 0.1183 compared to AUD 0.0753 a year ago.

Latest news about The iQ Group Global Ltd.

Harvard Wyss Institute’S Erapid Sensor Technology Licensed to Antisoma Therapeutics to Facilitate Infectious and Immune Disease and Cancer Diagnostics	08/22/08	CI
The Iq Group Global Ltd. Reports Earnings Results for the Full Year Ended June 30, 2021	13/21/13	CI
The iQ Group Global Ltd. Auditor Raises 'Going Concern' Doubt	13/21/13	CI
The Iq Group Global Ltd. Reports Earnings Results for the Half Year Ended December 31, 2020	12/21/12	CI
The Iq Group Global Ltd. Reports Earnings Results for the Full Year Ended June 30, 2020	12/20/12	CI
The Iq Group Global Ltd. Reports Earnings Results for the Half Year Ended December 31, 2019	16/20/16	CI
IQnovate Ltd will Change its Name to The iQ Group Global Ltd	30/19/30	CI
Iqnovate Limited Reports Earnings Results for the Full Year Ended June 30, 2019	16/19/16	CI
Iqnovate Ltd. Reports Earnings Results for the Half Year Ended December 31, 2018	18/19/18	CI
IQnovate Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2018	30/18/30	CI
IQnovate Limited announced that it has received AUD 1.693483 million in funding a group of investors	19/18/19	CI
IQnovate Limited Reports Unaudited Consolidated Earnings Results for the Year Ended June 30, 2018	15/18/15	CI
IQnovate Limited announced that it has received AUD 0.60775 million in funding	06/18/06	CI
IQnovate Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2017	16/18/16	CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Year Ended June 30, 2017	20/17/20	CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Half Year Ended December 31, 2016	16/17/16	CI
IQnovate Ltd. cancelled the acquisition of 50% stake in Emedia Creative Pty Ltd.	17/16/17	CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Year Ended June 30, 2016	13/16/13	CI
IQN Extends and Expands its Strategic Alliance with Bartech Group	13/16/13	CI
IQnovate Ltd. Reports Consolidated Earnings Results for the Half Year Ended December 31, 2015	15/16/15	CI
IQnovate Ltd. agreed to acquire 50% stake in Emedia Creative Pty Ltd.	17/15/17	CI
IQnovate Ltd. announced that it expects to receive NZD 5 million in funding	11/15/11	CI
24,512,498 Ordinary Shares of IQnovate Ltd are subject to a Lock-Up Agreement Ending on 15-DEC-2013.	15/13/15	CI
IQnovate Ltd. announced that it has received AUD 2 million in funding.	12/13/12	CI
1,437,499 Ordinary Shares of IQnovate Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2012.	15/12/15	CI

Chart The iQ Group Global Ltd.

Duration

Period

More charts

Company Profile

The IQ Group Global Ltd is an Australia-based life sciences and medical technology company. The Company is engaged in providing intellectual asset property management services, and integrated scientific advisory to the biopharmaceutical industry. It finds, funds and develops bioscience discoveries to create medical innovations and provide the fundamental basis for pharmaceuticals and devices that global populations of patients, hospitals and healthcare providers rely. Its platform technology, TEX Core is focused to develop compounds that are designed to be tumor localizing, well-tolerated, magnetic resonance imaging (MRI)-detectable in multiple solid tumors, including cancer cells that fail to respond to therapies. The Biosensor platform is a small, organic strip that puts accurate, timely diagnosis to patients and their primary health practitioners. The Company's platform is used for multiple diagnostic tests and translation medicine.

Sector

More about the company